TRCT
PCVX icon

Tower Research Capital (TRC)’s Vaxcyte PCVX Stock Holding History

Tower Research Capital (TRC)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
4,988
-7,172
-59% -$390K 0.01% 1416
2026
Q1 		$707K Buy
12,160
+5,002
+70% +$272K 0.02% 706
2025
Q4 		$330K Buy
7,158
+1,166
+19% +$52.1K 0.01% 1090
2025
Q3 		$216K Sell
5,992
-3,314
-36% -$110K 0.01% 1398
2025
Q2 		$303K Buy
9,306
+5,672
+156% +$186K 0.01% 1414
2025
Q1 		$137K Sell
3,634
-10,802
-75% -$864K ﹤0.01% 1597
2024
Q4 		$1.18M Buy
14,436
+13,458
+1,376% +$1.34M 0.02% 551
2024
Q3 		$112K Sell
978
-22,557
-96% -$2.03M ﹤0.01% 2144
2024
Q2 		$1.78M Buy
23,535
+22,495
+2,163% +$1.53M 0.03% 477
2024
Q1 		$71K Sell
1,040
-16,509
-94% -$1.14M ﹤0.01% 2040
2023
Q4 		$1.1M Buy
17,549
+16,386
+1,409% +$851K 0.01% 791
2023
Q3 		$59.3K Sell
1,163
-3,500
-75% -$173K ﹤0.01% 2403
2023
Q2 		$233K Buy
4,663
+2,166
+87% +$103K 0.01% 1450
2023
Q1 		$94K Buy
2,497
+1,755
+237% +$74.4K ﹤0.01% 1930
2022
Q4 		$35K Sell
742
-7,200
-91% -$283K ﹤0.01% 2615
2022
Q3 		$191K Sell
7,942
-453
-5% -$11.5K ﹤0.01% 1982
2022
Q2 		$183K Buy
8,395
+7,416
+758% +$172K ﹤0.01% 1829
2022
Q1 		$23K Sell
979
-648
-40% -$14.2K ﹤0.01% 3399
2021
Q4 		$38K Buy
1,627
+57
+4% +$1.33K ﹤0.01% 3006
2021
Q3 		$40K Sell
1,570
-890
-36% -$21.6K ﹤0.01% 3129
2021
Q2 		$55K Sell
2,460
-424
-15% -$8.68K ﹤0.01% 2952
2021
Q1 		$57K Buy
2,884
+732
+34% +$18.4K ﹤0.01% 3008
2020
Q4 		$57K Sell
2,152
-609
-22% -$22.6K ﹤0.01% 2976
2020
Q3 		$136K Buy
+2,761
New +$110K ﹤0.01% 2901

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Tower Research Capital (TRC)'s PCVX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Vaxcyte (PCVX) stake by 59% in Q2 2026, selling an estimated $390K and leaving 4,988 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #1416.

Tower Research Capital (TRC) first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.78M in Q2 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Tower Research Capital (TRC) held 4,988 shares of Vaxcyte worth $290K as of Q2 2026.
  • Tower Research Capital (TRC) sold 7,172 Vaxcyte shares in Q2 2026, an estimated $390K.
  • Vaxcyte made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1416 holding.
  • Tower Research Capital (TRC) first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Vaxcyte position peaked at $1.78M in Q2 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.